MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

Начало・Списък с акции・Design Therapeutics Inc

Design Therapeutics Inc

Отворен

12.01 -1.56

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.76

Максимум

12.22

Ключови измерители
By Trading Economics
Приходи	1M -16M
Служители	54
EBITDA	-1.2M -18M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+38.02% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	57M 640M
Предишно отваряне	13.57
Предишно затваряне	12.01

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

3.26 / 3.63 Подкрепа & съпротива

Design Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.04.2026 г., 23:17 ч. UTC

Печалби

Samsung Forecasts Record First-Quarter Operating Profit

6.04.2026 г., 23:00 ч. UTC

Горещи акции

Stocks to Watch: Health Insurers, Mawson, Owlet

6.04.2026 г., 22:13 ч. UTC

Значими двигатели на пазара

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6.04.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6.04.2026 г., 17:09 ч. UTC

Значими двигатели на пазара

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6.04.2026 г., 16:56 ч. UTC

Значими събития в новините

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6.04.2026 г., 14:47 ч. UTC

Значими двигатели на пазара

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6.04.2026 г., 23:58 ч. UTC

Пазарно говорене

Значими събития в новините

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6.04.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6.04.2026 г., 23:15 ч. UTC

Пазарно говорене

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6.04.2026 г., 22:52 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

6.04.2026 г., 22:52 ч. UTC

Пазарно говорене

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6.04.2026 г., 22:14 ч. UTC

Пазарно говорене

Correction to Live Cattle Futures Article

6.04.2026 г., 20:56 ч. UTC

Пазарно говорене

Mexican Private Consumption Fell in January -- Market Talk

6.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

6.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.04.2026 г., 19:58 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.04.2026 г., 19:58 ч. UTC

Пазарно говорене

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6.04.2026 г., 19:11 ч. UTC

Пазарно говорене

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6.04.2026 г., 19:06 ч. UTC

Пазарно говорене

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6.04.2026 г., 19:03 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

6.04.2026 г., 19:03 ч. UTC

Пазарно говорене

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6.04.2026 г., 18:36 ч. UTC

Придобивния, сливания и поглъщания

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6.04.2026 г., 17:59 ч. UTC

Пазарно говорене

Значими събития в новините

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6.04.2026 г., 17:13 ч. UTC

Придобивния, сливания и поглъщания

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6.04.2026 г., 16:33 ч. UTC

Пазарно говорене

Oil Futures Steady as Market Awaits Trump -- Market Talk

6.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.04.2026 г., 14:59 ч. UTC

Печалби

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Design Therapeutics Inc Прогноза

Ценова цел

By TipRanks

38.02% нагоре

12-месечна прогноза

Среден 15.5 USD 38.02%

Висок 18 USD

Нисък 14 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Design Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Design Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

3.26 / 3.63Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.